Compliance drives demand.
GMP and GDP require controlled conditions and reliable records. Proposed EU GMP revisions would sharpen expectations for digital systems.
Swiss pharmaceutical software
Compliance is mandatory.You choose the supplier.
Frigalis is developing software to bring pharmaceutical temperature monitoring and compliance records together.
Seeking a lead investor or strategic partner.
FrigalisFor prospective investors and strategic partners
VentureConnect
Forum
Basel, Switzerland
Book a meetingAbout the ForumThe investment opportunity
Regulatory change
A window of opportunity
An opening for new suppliers
When spreadsheets and legacy systems cannot provide the required controls, companies need a replacement and a supplier they can trust.
The stakes are real.
For manufacturers, serious GMP failures can mean product recalls and suspended licences. Reliable evidence matters.
Regulatory context
Current obligations and proposed changes are distinct. The EU GMP revisions cited here are proposals, not adopted rules. We see a market-entry opportunity where existing systems cannot be adapted.
Why Frigalis
From fragmented records to coherent evidence
We are developing Frigalis to reduce the work of assembling compliance records, helping pharmaceutical teams review what happened across storage and transport.
Managing Director
Dr. Claus Gawel
Claus translates pharmaceutical regulation into product requirements and leads Frigalis’s business development. He brings in-house experience from Johnson & Johnson and AbbVie.
Professional background
CTO
Pavel Zhukov
Pavel leads Frigalis’s systems architecture, software engineering, testing and deployment. His experience includes technology projects with Goldman Sachs, Deloitte and Google.
Based in Basel
Basel brings together leading pharmaceutical manufacturers and specialist distributors, giving Frigalis proximity to potential customers, industry expertise and a strong base for international growth.
Invest in European growth
Fund the market launch, build a strong sales and delivery team, and scale Frigalis from its Swiss base across Europe’s pharmaceutical markets.
Our mission: compete with multinationals and bring value creation back to Basel’s innovation ecosystem.
Discuss an investmentInvestor FAQ
The company, the opportunity
and the financing round
What is Frigalis, and what will it do?
Frigalis is developing Swiss software for pharmaceutical temperature monitoring and compliance records across storage and transport.
It is intended to bring fragmented records into coherent evidence where spreadsheets and legacy systems fall short.
Basel’s pharmaceutical companies, specialist talent and international connections provide a strong base for our ambition to grow worldwide.
Why is now the time to invest?
Regulatory change can prompt customers to reconsider their systems and suppliers. We see a limited window to establish Frigalis before companies commit to their next systems and suppliers. The financing would help us enter the market during this window.
What investment is Frigalis seeking?
We are seeking a lead investor or strategic partner and intend to build a financing round through equity or convertible loans. Alongside capital, we welcome relevant industry experience and commercial connections.
Why start in Basel?
Basel brings together global pharmaceutical companies, specialist talent and international connections. That proximity gives us a strong starting point to understand customer needs, build relationships and pursue growth beyond Switzerland.
Explore Basel’s life sciences ecosystemIs the product available today?
Not yet. Frigalis is in development. We discuss product progress and potential collaboration directly with interested investors and strategic partners.
For prospective investors and strategic partners
Basel, SwitzerlandMeet us
in Basel.
We’re seeking a lead investor or strategic partner. Let’s discuss the opportunity and the financing round.
Book a meeting
Email us your availability.
We’ll confirm the details with you.